Corporate Office

2223 Avenida de la Playa

Suite 206

La Jolla, CA 92037

+1 858 203 1169

Laboratory

3550 General Atomics Ct.

Bldg G02, #137

San Diego, CA 92121

+1 858 203 1168

Abreos France

232 Boulevard de Sainte Marguerite

13009 Marseille, France

+33 06 07 54 58 25

Recent news

Monator.png

Abreos Biosciences Announces Research Collaboration with FDA-CDER

March 26, 2019

Abreos Biosciences Launches Laboratory Developed Test for Precision Dose Monitoring of Natalizumab (Tysabri).

August 28, 2018

Abreos Biosciences presented at the Biocom Global Partnering Life Sciences Partnering Conference.

March 1, 2018

Abreos Biosciences won Silicon Valley's Most Promising Company Award at the Precision Medicine World Conference 2018.

January 24, 2018

Abreos Biosciences competed as a finalist in the MedTech Innovator 2017 Competition.

September 26, 2017

Abreos Biosciences was selected as one of 20 companies to participate in the MedTech Innovator Accelerator.

May 30, 2017

The Journal of Precision Medicine featured Abreos Biosciences in its recent article, "Ready for a Dose of Reality?"

May 30, 2017

Abreos Biosciences' participation in the MedTech Innovator pitch competition was featured in BIOCOM's coverage of the HealthTech LA event.

March 9, 2017

Abreos Biosciences has been selected as one of MedTech Innovator's Top 100 emerging medical technology companies.

March 4, 2017

Bradley Messmer, the CEO of Abreos Biosciences, Will Participate as a Finalist in the Swimming with Sharks Competition on Wednesday, February 24th and Will Present on Point-of-Care Diagnostics for Personalized Dosing of Biologics on Friday, February 22nd.

February 22-24, 2017

CEO Bradly Messmer Presented on the San Diego Biotech Industry Panel during the Cancer Moonshot Panel Summit Hosted by the American Cancer Society and Biocom

December 12, 2016

Immune System, Unleashed by Cancer Therapies, Can Attack Organs 

December 3, 2016

Bradley Messmer, the CEO of Abreos Biosciences, Presented Peptide Mimics that Allow for Therapeutic Drug Monitoring of Biologic Drugs at AAPS 2016 

November 14, 2016

Abreos Biosciences Announces The Formation Of A French Subsidiary, Abreos France, And A Research Collaboration With The Institut Paoli-Calmettes For Therapeutic Drug Monitoring Of Biologics

October 3, 2016

Biocom’s 9th Annual DeviceFest Conference: Congrats to Abreos Biosciences

August 30, 2016

Biotech Startup Stories: Abreos Biosciences

August 22, 2016

Triton Technology Fund Announces Their Investment in Abreos Biosciences

 

June 28, 2016

Abreos Biosciences and True Diagnostics Sign Collaboration Agreement for Novel Biologics Tests

 

March 8, 2016

Abreos Biosciences is selected as one of four finalists to compete at the 2015 VC Pitchfest organized by the San Diego Venture Group

 

December 3, 2015

Bradley Messmer, founder and CEO of Abreos Biosciences, is speaking at the Molecular Tumor Board Meeting about precision dosing of biologic drugs and point-of-care testing

 

August 26, 2015

Abreos Biosciences earns the "Cool Companies" designation by the San Diego Venture Group

 

June 27, 2015

Bradley Messmer, founder and CEO of Abreos Biosciences, discusses the future of nanotechnology at the Rock Stars of Innovation Summit

 

June 10, 2015

Abreos Biosciences is developing partnerships during the Second Edition of BIOCOM / FRENCH BIOBEACH Trade Delegation to the South of France

 

April 27, 2015

Abreos Biosciences is featured in Nature News for impressive performance at NIH I-Corps

 

March 25, 2015

Abreos Biosciences is awarded a Phase I SBIR grant to develop a rapid lateral flow based assay for endotoxin detection

 

March 1, 2015

Abreos Biosciences is awarded a Phase I SBIR grant to develop MuDPAQ, a sequencing-based proteomics platform using DeNAno technology

 

Januray 15, 2015

Abreos Biosciences selected as one of 20 companies to participate in the inaugural I-Corps program sponsored by the NIH

 

October  7, 2014

Abreos Biosciences is awarded a Phase I STTR grant from the National Cancer Institute to develop lateral flow immunoassays for therapeutic drug dosing

 

September 23, 2014

Bradley Messmer reveals to the Times of San Diego how Abreos Biosciences provides a solution for the rapid identification of counterfeit pharmaceuticals

 

June 12, 2014

Abreos Biosciences graduates from the CONNECT Springboard program and wins the CONNECT Capital Competition

 

April 23, 2014

Abreos Biosciences is awarded a Phase I SBIR grant from the National Cancer Institute to develop lateral flow immunoassays for monoclonal antibody authentication

 

April 15, 2014

Abreos Biosciences wins the prestigious Tech Coast Angels Quick Pitch “Best Content” award

 

September 26, 2013

Abreos Biosciences’ founder Bradley Messmer discusses how to protect patients from counterfeit medication on The Empowered Patient radio show

 

September 13, 2013